Endra Life Sciences INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
L1 Capital Global Opportunities Master Fund, Ltd. has reported a 3.0% beneficial ownership stake in ENDRA Life Sciences Inc., primarily through warrants.
NASDAQ
S.H.N. Financial Investments Ltd. reported a 3.0% beneficial ownership in ENDRA Life Sciences Inc. through Series A Warrants, a significant reduction from a prior common stock holding.
NASDAQ
John Carter Lipman has disclosed a 9.99% beneficial ownership stake in ENDRA Life Sciences Inc., primarily for passive investment purposes.
NASDAQ
ATW Master Fund V LP and its affiliates have disclosed a 9.9% beneficial ownership stake in ENDRA Life Sciences Inc., totaling 116,024 common shares.
NASDAQ
SCHEDULE 13G/A: L1 Capital Global Opportunities Master Fund Discloses 6.22% Stake in ENDRA Life Sciences
L1 Capital Global Opportunities Master Fund, Ltd. has filed an amended Schedule 13G, disclosing a 6.22% beneficial ownership stake in ENDRA Life Sciences Inc. as of December 31, 2024.